CIBD
MCID: CYT004
MIFTS: 31

Cytomegalic Inclusion Disease (CIBD) malady

Categories: Rare diseases

Aliases & Classifications for Cytomegalic Inclusion Disease

Aliases & Descriptions for Cytomegalic Inclusion Disease:

Name: Cytomegalic Inclusion Disease 50
Cytomegalic Inclusion Body Disease 50 51 69
Giant Cell Inclusion Disease 50 51
Cytomegalovirus Infections 69
Cibd 50

Classifications:



Summaries for Cytomegalic Inclusion Disease

NINDS : 51 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system.

MalaCards based summary : Cytomegalic Inclusion Disease, also known as cytomegalic inclusion body disease, is related to pneumonia and leukemia, and has symptoms including fever and pruritus. The drugs Cyclosporine and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and bone.

Wikipedia : 71 Cytomegalic inclusion body disease (CIBD) is a series of signs and symptoms caused by cytomegalovirus... more...

Related Diseases for Cytomegalic Inclusion Disease

Diseases related to Cytomegalic Inclusion Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 49)
id Related Disease Score Top Affiliating Genes
1 pneumonia 10.2
2 leukemia 10.1
3 cerebritis 10.1
4 cytomegalovirus infection 10.0
5 toxoplasmosis 10.0
6 aspergillosis 9.9
7 childhood leukemia 9.9
8 herpes simplex 9.9
9 chorioretinitis 9.9
10 hepatitis 9.9
11 macroglobulinemia 9.9
12 thrombocytopenia 9.9
13 neonatal jaundice 9.9
14 lymphoma 9.9
15 rhinitis 9.9
16 mucositis 9.8
17 autoimmune hemolytic anemia 9.8
18 siderosis 9.8
19 refractory anemia 9.8
20 wiskott-aldrich syndrome 9.8
21 osteomalacia 9.8
22 myocarditis 9.8
23 acute leukemia 9.8
24 hypoparathyroidism 9.8
25 adult t-cell leukemia 9.8
26 disseminated intravascular coagulation 9.8
27 hodgkin's granuloma 9.8
28 burns 9.8
29 uveitis 9.8
30 lymphosarcoma 9.8
31 glomerulonephritis 9.8
32 urethritis 9.8
33 rubella 9.8
34 hemolytic anemia 9.8
35 cholestasis 9.8
36 candidiasis 9.8
37 intrahepatic cholestasis 9.8
38 meningitis 9.8
39 encephalitis 9.8
40 ulcerative colitis 9.8
41 retinitis 9.8
42 congenital cytomegalovirus 9.8
43 colitis 9.8
44 herpes simplex encephalitis 9.8
45 porencephaly 9.8
46 polymyositis 9.8
47 inguinal hernia 9.8
48 t-cell leukemia 9.8
49 prurigo nodularis 9.8

Graphical network of the top 20 diseases related to Cytomegalic Inclusion Disease:



Diseases related to Cytomegalic Inclusion Disease

Symptoms & Phenotypes for Cytomegalic Inclusion Disease

UMLS symptoms related to Cytomegalic Inclusion Disease:


fever, pruritus

Drugs & Therapeutics for Cytomegalic Inclusion Disease

Drugs for Cytomegalic Inclusion Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3 79217-60-0, 59865-13-3 5284373 6435893
2
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
3
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
5
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
6
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
9
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
10
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
11
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 63585-09-1, 4428-95-9 3415
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
15
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
16
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
17
Probenecid Approved Phase 4,Phase 2,Phase 1 57-66-9 4911
18
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
20
Infliximab Approved Phase 4 170277-31-3
21
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
22
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
23
Pancrelipase Approved Phase 4 53608-75-6
24
Azathioprine Approved Phase 4 446-86-6 2265
25 tannic acid Approved, Nutraceutical Phase 4
26
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 4408-78-0 546
27 triamcinolone acetonide Phase 4
28 Prednisolone acetate Phase 4,Phase 3
29 glucocorticoids Phase 4,Phase 3
30 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 4,Phase 1
32 Neuroprotective Agents Phase 4
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Dermatologic Agents Phase 4
35 Hormone Antagonists Phase 4,Phase 3,Phase 2
36 Triamcinolone diacetate Phase 4
37 Triamcinolone hexacetonide Phase 4
38 Hormones Phase 4,Phase 3,Phase 2
39 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
40 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
44 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
45 Prednisolone hemisuccinate Phase 4,Phase 3
46 Prednisolone phosphate Phase 4,Phase 3
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
49 Protective Agents Phase 4,Phase 2
50 Antiemetics Phase 4

Interventional clinical trials:

(show top 50) (show all 323)
id Name Status NCT ID Phase
1 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
2 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4
3 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
4 Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients Unknown status NCT00364052 Phase 4
5 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4
6 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4
7 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
8 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients Completed NCT00436384 Phase 4
9 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
10 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4
11 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4
12 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4
13 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4
14 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4
15 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4
16 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4
17 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4
18 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4
19 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
20 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4
21 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4
22 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4
23 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4
24 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4
25 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4
26 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4
27 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4
28 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4
29 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4
30 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4
31 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Recruiting NCT02550639 Phase 4
32 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients Recruiting NCT01552369 Phase 4
33 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4
34 PTH - Preemptive Treatment for Herpesviridae Recruiting NCT02152358 Phase 4
35 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4
36 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4
37 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3
38 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3
39 A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) Unknown status NCT01157949 Phase 3
40 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3
41 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3
42 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3
43 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3
44 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3
45 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3
46 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3
47 MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3
48 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3
49 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3
50 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation Completed NCT00372229 Phase 3

Search NIH Clinical Center for Cytomegalic Inclusion Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Cytomegalic Inclusion Disease

Anatomical Context for Cytomegalic Inclusion Disease

MalaCards organs/tissues related to Cytomegalic Inclusion Disease:

39
Kidney, Lymph Node, Bone, Placenta, Skin, Liver, Salivary Gland

Publications for Cytomegalic Inclusion Disease

Articles related to Cytomegalic Inclusion Disease:

(show top 50) (show all 196)
id Title Authors Year
1
Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. ( 10740207 )
2000
2
A fatal case of congenital cytomegalic inclusion disease following recurrent maternal infection. ( 8590396 )
1995
3
Disseminated cutaneous cytomegalic inclusion disease resembling prurigo nodularis in a HIV-infected patient: a case report and literature review. ( 7964230 )
1993
4
Temporal bone histopathology 14 years after cytomegalic inclusion disease: a case study. ( 8395628 )
1993
5
Cytomegalic inclusion disease presenting acute intrahepatic cholestasis. ( 1338619 )
1992
6
Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involving the brain. ( 1846993 )
1991
7
Salivary gland oncocytes in African hedgehogs (Atelerix albiventris) mimicking cytomegalic inclusion disease. ( 1655834 )
1991
8
Successful treatment of disseminated cutaneous cytomegalic inclusion disease associated with Hodgkin's disease. ( 1847957 )
1991
9
A viral infection causing cytomegalic inclusion disease in the renal epithelium of the platypus (Ornithorhynchus anatinus). ( 2154629 )
1990
10
Spontaneous disseminated cytomegalic inclusion disease in an ageing laboratory mouse. ( 2843585 )
1988
11
Evaluation of diagnostic criteria for mucosal cytomegalic inclusion disease in the acquired immune deficiency syndrome. ( 2825515 )
1987
12
Glomerulonephritis in congenital cytomegalic inclusion disease. ( 3019866 )
1986
13
Reactivation of congenital cytomegalic inclusion disease in an infant with HTLV-III associated immunodeficiency: a CT-pathologic correlation. ( 3009568 )
1986
14
The incidence of cytomegalic inclusion disease (CID) in an obstetric teaching hospital, 1975-1984. ( 3002314 )
1985
15
Cytomegalic inclusion disease after recurrent maternal infection. ( 2865630 )
1985
16
Disseminated intravascular coagulation induced by generalized cytomegalic inclusion disease during steroid therapy for polymyositis. ( 2994360 )
1985
17
Sudden infant death with congenital cytomegalic inclusion disease. ( 6324573 )
1984
18
Neonatal cytomegalic inclusion disease in a set of twins one member of whom was a hydropic stillbirth the other completely uninfected. Case report. ( 6299328 )
1983
19
Two-dimensional ultrasonography of the brain: its diagnostic usefullness in herpes simplex encephalitis and cytomegalic inclusion disease. ( 6311039 )
1983
20
Computed tomography in the diagnosis of congenital cytomegalic inclusion disease. ( 6293102 )
1982
21
Cytomegalic inclusion disease diagnosed endoscopically. ( 6257456 )
1981
22
Cytomegalic inclusion disease of the skin. ( 6261699 )
1981
23
Generalized cytomegalic inclusion disease in neonates and infants. ( 6249068 )
1980
24
Adult pulmonary cytomegalic inclusion disease: report of a case. ( 6244337 )
1980
25
Adult cytomegalic inclusion disease. ( 6259726 )
1980
26
Adult T-cell leukemia with generalized cytomegalic inclusion disease and pneumocystis carinii pneumonia. ( 233285 )
1979
27
Cytomegalic inclusion disease: a study of fifty-five autopsies. ( 226645 )
1979
28
Osseous lesions and pathologic fractures in congenital cytomegalic inclusion disease: report of a case. ( 231493 )
1979
29
Noncirrhotic portal fibrosis following neonatal cytomegalic inclusion disease. ( 213550 )
1978
30
Hepatic calcification in congenital cytomegalic inclusion disease. ( 205645 )
1978
31
Ocular cytomegalic inclusion disease in the adult. ( 214905 )
1977
32
Fatal cytomegalic inclusion disease. Associated skin manifestations in a renal transplant patient. ( 201217 )
1977
33
The otologic manifestations of cytomegalic inclusion disease - a case report. ( 193219 )
1977
34
Calcification in liver associated with congenital cytomegalic inclusion disease. ( 190372 )
1977
35
Generalized porcine cytomegalic inclusion disease: distribution of cytomegalic cells and virus. ( 178692 )
1976
36
Pseudoglioma and cytomegalic inclusion disease. ( 192400 )
1976
37
Disseminated cytomegalic inclusion disease in an adult with cirrhosis of liver and review of literatures. ( 190080 )
1976
38
Bone changes in congenital cytomegalic inclusion disease. ( 165786 )
1975
39
Cytomegalic inclusion disease with petechiae and thrombocytopenia at birth. ( 166764 )
1975
40
Cytomegalic inclusion disease in the east African headgehog. ( 167206 )
1975
41
An autopsy case of generalized cytomegalic inclusion disease associated with Pneumocystis carinii pneumonia. ( 173920 )
1975
42
An autopsy case of isolated myocarditis probably associated with infectious mononucleosis and disseminated cytomegalic inclusion disease. ( 4365594 )
1974
43
Massive fetal ascites, urethral atresia, and cytomegalic inclusion disease. ( 4365977 )
1974
44
Unusual glomerular change in cytomegalic inclusion disease. ( 4374799 )
1974
45
Fecal excretion of cytomegalovirus in disseminated cytomegalic inclusion disease. ( 4365949 )
1974
46
Letter: Bilateral eventration of the diaphragm in a neonate with congenital cytomegalic inclusion disease. ( 4358655 )
1973
47
Cytomegalic inclusion disease. Pediatric grand rounds. ( 4347884 )
1973
48
Persistent albuminuria and meningitis caused by congenital cytomegalovirus infection. A case report of cytomegalic inclusion disease. ( 4369003 )
1973
49
A sensitive cell culture system for the virus of porcine inclusion body rhinitis (cytomegalic inclusion disease). ( 4350592 )
1973
50
Monoclonal macroglobulinemia and cytomegalic inclusion disease. ( 4350589 )
1973

Variations for Cytomegalic Inclusion Disease

Expression for Cytomegalic Inclusion Disease

Search GEO for disease gene expression data for Cytomegalic Inclusion Disease.

Pathways for Cytomegalic Inclusion Disease

GO Terms for Cytomegalic Inclusion Disease

Sources for Cytomegalic Inclusion Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....